Alexandria Forbes, who serves as President and CEO of MeiraGTx Holdings plc (NASDAQ: MGTX), sold 62,000 ordinary shares of the company on March 24, 2026, generating approximately $459,420 in gross proceeds. The sales were completed in multiple transactions at prices that ranged between $7.27 and $7.56 per share and carried a weighted average price of $7.41.
The disposition was executed under a Rule 10b5-1 trading plan that MeiraGTx disclosed was adopted on November 18, 2025. Following the transactions, Forbes is reported to directly hold 1,449,695 ordinary shares of MeiraGTx Holdings plc.
MeiraGTx’s share sale comes as the company shows signs of financial stress. InvestingPro data cited by the company notes a current ratio of 0.22 and indicates the firm is depleting cash reserves quickly. Despite those liquidity metrics, an InvestingPro Fair Value assessment included in the disclosure suggests the stock may be undervalued at present.
Alongside the insider sale, MeiraGTx announced strategic business developments. The company has entered into an exclusive licensing agreement with ZipBio centered on novel gene therapies for Geographic Atrophy, a progressive eye disease. The agreement grants MeiraGTx exclusive rights to ZipBio’s first-in-class therapies that focus on the complement pathway. Financial terms for the license were not disclosed; the agreement reportedly includes upfront payments as well as possible milestone and royalty payments.
In a separate capital-structure move, MeiraGTx agreed to purchase 2.3 million ordinary shares from Perceptive Life Sciences Master Fund, Ltd. The repurchase was executed at $7.91 per share, for a total price of $18,193,000. Company disclosures say the sale to MeiraGTx was part of Perceptive Master Fund’s year-end portfolio tax optimization activities.
These items - an insider sale under a prearranged plan, an exclusive licensing deal for gene therapies aimed at Geographic Atrophy, and a material share repurchase from a fund - were disclosed together, providing investors with contemporaneous information on both management transactions and corporate strategy. The company’s market capitalization was cited at $601 million in the related disclosures.
The materials provided do not disclose additional details about the timing of cash payments tied to the ZipBio license, nor do they offer forward guidance tied to the company’s liquidity position. MeiraGTx’s filings show the factual elements described here without further commentary on prospective operational outcomes.